R. Gonzales

Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma

J. Kirkwood, A. Ribas, M. Milhem, 2018, Clinical Trials.

Superoxide dismutase, catalase, and glutathione peroxidase in red blood cells from patients with malignant diseases.

P. Boivin, C. Auclair, R. Gonzales, 1984, Cancer research.

Adhering to the guidelines: rates of BRCA mutation using NCCN genetic testing criteria

Jaime, Shaheen, J. Kirkwood, 2017 .

A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.

J. Kirkwood, K. Lewis, W. Samlowski, 2007 .